Innoviva, Inc. (INVA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Innoviva, Inc. (INVA) closed at USD 20.86 on 2026-10-15, a change of +18.7 % over the past year, with a market capitalization of USD 1.5B.

Innoviva, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Innoviva, Inc. key figures

Previous close

USD 20.86 (2026-10-15)

1-year change

+18.7 %

Market cap

USD 1.5B

Enterprise value

USD 1.25B

P/E ratio (trailing)

4.86

P/E ratio (forward)

9.40

EPS (trailing)

4.28

EPS (forward)

2.21

PEG ratio

3.12

Price to book

1.22

Revenue growth

19.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.79

Employees

159

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Innoviva, Inc. and compare it with other stocks.